Goldman Sachs’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$27.8M Buy
457,900
+250,500
+121% +$14.6M ﹤0.01% 2129
2025
Q4
$11.2M Sell
207,400
-762,200
-79% -$36.7M ﹤0.01% 2991
2025
Q3
$43.7M Buy
969,600
+814,200
+524% +$38M 0.01% 1525
2025
Q2
$7.19M Sell
155,400
-231,200
-60% -$11.3M ﹤0.01% 3072
2025
Q1
$23.6M Sell
386,600
-118,100
-23% -$6.88M ﹤0.01% 1869
2024
Q4
$28.5M Sell
504,700
-310,000
-38% -$17.3M ﹤0.01% 1787
2024
Q3
$42.2M Sell
814,700
-2,140,500
-72% -$100M 0.01% 1386
2024
Q2
$123M Sell
2,955,200
-332,700
-10% -$14.9M 0.02% 698
2024
Q1
$178M Buy
3,287,900
+320,700
+11% +$16.3M 0.03% 538
2023
Q4
$152M Buy
2,967,200
+2,266,500
+323% +$119M 0.03% 590
2023
Q3
$40.7M Buy
700,700
+538,300
+331% +$33M 0.01% 1232
2023
Q2
$10.4M Buy
162,400
+108,400
+201% +$7.27M ﹤0.01% 2414
2023
Q1
$3.74M Sell
54,000
-216,700
-80% -$15.3M ﹤0.01% 3329
2022
Q4
$19.5M Buy
270,700
+80,900
+43% +$6.1M ﹤0.01% 1986
2022
Q3
$13.5M Sell
189,800
-104,700
-36% -$7.59M ﹤0.01% 2227
2022
Q2
$22.7M Buy
294,500
+163,600
+125% +$12.5M 0.01% 1795
2022
Q1
$9.56M Sell
130,900
-387,000
-75% -$26M ﹤0.01% 2739
2021
Q4
$32.3M Buy
517,900
+203,200
+65% +$11.9M 0.01% 1695
2021
Q3
$18.6M Buy
314,700
+207,000
+192% +$13.6M ﹤0.01% 2129
2021
Q2
$7.2M Sell
107,700
-289,600
-73% -$18.9M ﹤0.01% 3015
2021
Q1
$25.1M Buy
397,300
+13,500
+4% +$840K 0.01% 1751
2020
Q4
$23.8M Buy
383,800
+168,300
+78% +$10.3M 0.01% 1720
2020
Q3
$13M Sell
215,500
-18,400
-8% -$1.11M ﹤0.01% 2087
2020
Q2
$13.8M Buy
233,900
+54,200
+30% +$3.24M ﹤0.01% 1997
2020
Q1
$10M Sell
179,700
-930,100
-84% -$56.8M ﹤0.01% 2081
2019
Q4
$71.2M Buy
1,109,800
+377,600
+52% +$21.6M 0.02% 909
2019
Q3
$37.1M Sell
732,200
-603,400
-45% -$28.4M 0.01% 1319
2019
Q2
$60.6M Sell
1,335,600
-575,400
-30% -$26.8M 0.02% 1016
2019
Q1
$91.2M Buy
1,911,000
+1,362,400
+248% +$67.9M 0.03% 718
2018
Q4
$28.5M Buy
548,600
+99,700
+22% +$5.36M 0.01% 1516
2018
Q3
$27.9M Sell
448,900
-768,500
-63% -$45.6M 0.01% 1672
2018
Q2
$67.4M Buy
1,217,400
+621,100
+104% +$33.5M 0.02% 1003
2018
Q1
$37.7M Sell
596,300
-113,800
-16% -$7.32M 0.01% 1378
2017
Q4
$43.5M Sell
710,100
-341,100
-32% -$21.3M 0.01% 1391
2017
Q3
$67M Sell
1,051,200
-168,300
-14% -$9.83M 0.02% 1079
2017
Q2
$68M Buy
1,219,500
+224,000
+23% +$12.2M 0.02% 1043
2017
Q1
$54.1M Sell
995,500
-663,900
-40% -$36.4M 0.01% 1174
2016
Q4
$97M Buy
1,659,400
+776,000
+88% +$42.4M 0.03% 792
2016
Q3
$47.6M Sell
883,400
-75,500
-8% -$4.85M 0.01% 1246
2016
Q2
$70.5M Buy
958,900
+583,600
+156% +$41.2M 0.02% 876
2016
Q1
$24M Sell
375,300
-390,300
-51% -$24.6M 0.01% 1588
2015
Q4
$52.7M Buy
765,600
+113,600
+17% +$7.51M 0.02% 1084
2015
Q3
$38.6M Buy
652,000
+311,000
+91% +$19.7M 0.01% 1228
2015
Q2
$22.7M Sell
341,000
-23,200
-6% -$1.53M 0.01% 1696
2015
Q1
$23.5M Buy
364,200
+127,000
+54% +$7.95M 0.01% 1642
2014
Q4
$14M Sell
237,200
-587,300
-71% -$33.1M ﹤0.01% 2088
2014
Q3
$42.2M Buy
824,500
+303,500
+58% +$15.2M 0.01% 1203
2014
Q2
$25.3M Sell
521,000
-626,800
-55% -$30.9M 0.01% 1615
2014
Q1
$59.6M Sell
1,147,800
-405,100
-26% -$21.6M 0.02% 924
2013
Q4
$82.5M Buy
1,552,900
+661,400
+74% +$33.7M 0.03% 727
2013
Q3
$41.3M Sell
891,500
-453,400
-34% -$19.9M 0.02% 1098
2013
Q2
$60.1M Buy
+1,344,900
New +$58.4M 0.02% 803

Other funds holding BMY

Goldman Sachs's BMY Position: Q1 2026 in Review

Goldman Sachs reduced its Bristol-Myers Squibb (BMY) stake by 23% in Q1 2026, selling an estimated $250M and leaving 14,054,518 shares worth $852M. The position accounts for 0.1% of the portfolio, ranked #196.

Goldman Sachs first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.19B in Q1 2023. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Goldman Sachs held 14,054,518 shares of Bristol-Myers Squibb worth $852M as of Q1 2026.
  • Goldman Sachs sold 4,288,459 Bristol-Myers Squibb shares in Q1 2026, an estimated $250M.
  • Bristol-Myers Squibb made up 0.1% of Goldman Sachs's portfolio in Q1 2026, its #196 holding.
  • Goldman Sachs first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Bristol-Myers Squibb position peaked at $1.19B in Q1 2023.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.